70.98 USD
+0.53 (+0.75%)
70.98 USD
0 (0%)
We assign a fundamental rating of 5 out of 10 to AXNX. AXNX was compared to 184 industry peers in the Health Care Equipment & Supplies industry. AXNX has a great financial health rating, but its profitability evaluates not so good. AXNX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AXNX has reported negative net income.
In the past year AXNX had a positive cash flow from operations.
AXNX had negative earnings in each of the past 5 years.
AXNX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
AXNX's Return On Assets of -0.73% is fine compared to the rest of the industry. AXNX outperforms 67.91% of its industry peers.
AXNX has a Return On Equity of -0.85%. This is in the better half of the industry: AXNX outperforms 68.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.73% | ||
| ROE | -0.85% | ||
| ROIC | N/A |
ROA(3y)-8.17%
ROA(5y)-15.38%
ROE(3y)-9.34%
ROE(5y)-18.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 76.59%, AXNX belongs to the best of the industry, outperforming 89.30% of the companies in the same industry.
In the last couple of years the Gross Margin of AXNX has grown nicely.
AXNX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.59% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.58%
GM growth 5Y5.57%
2. Health
2.1 Basic Checks
AXNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AXNX has been increased compared to 1 year ago.
AXNX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for AXNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
AXNX has an Altman-Z score of 20.38. This indicates that AXNX is financially healthy and has little risk of bankruptcy at the moment.
AXNX has a Altman-Z score of 20.38. This is amongst the best in the industry. AXNX outperforms 93.58% of its industry peers.
There is no outstanding debt for AXNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 20.38 |
ROIC/WACCN/A
WACC9.07%
2.3 Liquidity
AXNX has a Current Ratio of 8.16. This indicates that AXNX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 8.16, AXNX belongs to the best of the industry, outperforming 87.70% of the companies in the same industry.
AXNX has a Quick Ratio of 6.40. This indicates that AXNX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 6.40, AXNX belongs to the top of the industry, outperforming 85.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.16 | ||
| Quick Ratio | 6.4 |
3. Growth
3.1 Past
AXNX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -116.67%.
AXNX shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.08%.
The Revenue has been growing by 249.76% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-116.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)26.08%
Revenue growth 3Y48.67%
Revenue growth 5Y249.76%
Sales Q2Q%24.8%
3.2 Future
The Earnings Per Share is expected to grow by 69.51% on average over the next years. This is a very strong growth
Based on estimates for the next years, AXNX will show a quite strong growth in Revenue. The Revenue will grow by 19.14% on average per year.
EPS Next Y56.54%
EPS Next 2Y120.11%
EPS Next 3Y100.31%
EPS Next 5Y69.51%
Revenue Next Year23.72%
Revenue Next 2Y21.8%
Revenue Next 3Y20.53%
Revenue Next 5Y19.14%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
AXNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
AXNX is valuated quite expensively with a Price/Forward Earnings ratio of 81.39.
65.78% of the companies in the same industry are more expensive than AXNX, based on the Price/Forward Earnings ratio.
AXNX is valuated expensively when we compare the Price/Forward Earnings ratio to 23.84, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 81.39 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AXNX is valued a bit cheaper than 62.57% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, AXNX is valued a bit cheaper than 66.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 675.06 | ||
| EV/EBITDA | 603.04 |
4.3 Compensation for Growth
AXNX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as AXNX's earnings are expected to grow with 100.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y120.11%
EPS Next 3Y100.31%
5. Dividend
5.1 Amount
No dividends for AXNX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
70.98
+0.53 (+0.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners85.44%
Inst Owner Change0%
Ins Owners5.35%
Ins Owner Change0%
Market Cap3.63B
Revenue(TTM)431.90M
Net Income(TTM)-5.66M
Analysts68.42
Price Target73.33 (3.31%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-50.5%
Min EPS beat(2)-100%
Max EPS beat(2)-1.01%
EPS beat(4)1
Avg EPS beat(4)-49.29%
Min EPS beat(4)-215.13%
Max EPS beat(4)118.99%
EPS beat(8)5
Avg EPS beat(8)52.84%
EPS beat(12)9
Avg EPS beat(12)41.69%
EPS beat(16)11
Avg EPS beat(16)30.84%
Revenue beat(2)2
Avg Revenue beat(2)0.21%
Min Revenue beat(2)0.05%
Max Revenue beat(2)0.37%
Revenue beat(4)3
Avg Revenue beat(4)0.07%
Min Revenue beat(4)-0.36%
Max Revenue beat(4)0.37%
Revenue beat(8)7
Avg Revenue beat(8)1.85%
Revenue beat(12)11
Avg Revenue beat(12)3.83%
Revenue beat(16)13
Avg Revenue beat(16)4.5%
PT rev (1m)0.23%
PT rev (3m)0.23%
EPS NQ rev (1m)21.53%
EPS NQ rev (3m)21.53%
EPS NY rev (1m)-2.83%
EPS NY rev (3m)5.04%
Revenue NQ rev (1m)0.94%
Revenue NQ rev (3m)0.94%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)0.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 81.39 | ||
| P/S | 8.4 | ||
| P/FCF | 675.06 | ||
| P/OCF | 253.73 | ||
| P/B | 5.46 | ||
| P/tB | 7.53 | ||
| EV/EBITDA | 603.04 |
EPS(TTM)-0.01
EYN/A
EPS(NY)0.87
Fwd EY1.23%
FCF(TTM)0.11
FCFY0.15%
OCF(TTM)0.28
OCFY0.39%
SpS8.45
BVpS13
TBVpS9.42
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.73% | ||
| ROE | -0.85% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.59% | ||
| FCFM | 1.24% |
ROA(3y)-8.17%
ROA(5y)-15.38%
ROE(3y)-9.34%
ROE(5y)-18.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.58%
GM growth 5Y5.57%
F-Score6
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 71.48% | ||
| Cap/Sales | 2.07% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 271.41% | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.16 | ||
| Quick Ratio | 6.4 | ||
| Altman-Z | 20.38 |
F-Score6
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)24.04%
Cap/Depr(5y)70.74%
Cap/Sales(3y)1.01%
Cap/Sales(5y)3.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-116.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y56.54%
EPS Next 2Y120.11%
EPS Next 3Y100.31%
EPS Next 5Y69.51%
Revenue 1Y (TTM)26.08%
Revenue growth 3Y48.67%
Revenue growth 5Y249.76%
Sales Q2Q%24.8%
Revenue Next Year23.72%
Revenue Next 2Y21.8%
Revenue Next 3Y20.53%
Revenue Next 5Y19.14%
EBIT growth 1Y33.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year377.96%
EBIT Next 3Y82.88%
EBIT Next 5Y66.14%
FCF growth 1Y133.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y210.5%
OCF growth 3YN/A
OCF growth 5YN/A
Axonics Inc / AXNX FAQ
What is the ChartMill fundamental rating of Axonics Inc (AXNX) stock?
ChartMill assigns a fundamental rating of 5 / 10 to AXNX.
What is the valuation status for AXNX stock?
ChartMill assigns a valuation rating of 4 / 10 to Axonics Inc (AXNX). This can be considered as Fairly Valued.
Can you provide the profitability details for Axonics Inc?
Axonics Inc (AXNX) has a profitability rating of 3 / 10.